1 |
Aapro M, Launay-Vacher V (2012). Importance of monitoring renal function in patients with cancer. Cancer Treat Rev, 38, 235-40.
DOI
|
2 |
American Cancer Society (2008). Global cancer facts and figures 2008 2nd edition. [online]. [cited on March 28th, 2014] http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/ acspc-027766.pdf
|
3 |
Ardizzoni A, Boni L, Tiseo M, et al (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99, 847-57.
DOI
|
4 |
Arunkumar PA, Viswanatha GL, Radheshyam N, et al (2012). Science behind cisplatin-induced nephrotoxicity in humans: a clinical study. Asian Pac J Trop Biomed, 2, 640- 4.
DOI
|
5 |
BC Cancer Agency Cancer Drug Manual (2013). Cisplatin. [cited on June 3rd, 2013] http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Cisplatin.htm
|
6 |
Bell JS, Blacker N, LeBlanc VT, et al (2013). Prescribing for older people with chronic renal impairment. Aust Fam Physician, 42, 24-8.
|
7 |
Caglar K, Kinalp C, Arpaci F, et al (2002). Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of highdose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant, 17, 1931-5.
DOI
|
8 |
Chu E, Sartorelli AC (2012). Cancer chemotherapy. In 'Basic and Clinical Pharmacology', Eds Katzung BG, Masters SB, Trevor AJ. 12nd ed. McGraw-Hill Companies Inc., USA pp 949-75.
|
9 |
Corwin EJ (2008). Hypertension. Diabetes mellitus. In 'Handbook of Pathophysiology'. 3rd ed. Lippincott Williams and Wilkins, USA pp 430-34, 556-70.
|
10 |
de Jongh FE, van Veen RN, Veltman SJ, et al (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer, 88, 1199-206.
DOI
|
11 |
Erten C, Demir L, Somali I, et al (2013). Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev, 14, 3711-7.
DOI
|
12 |
Fine LG, Norman JT (2008). Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int, 74, 867-72.
DOI
|
13 |
Food and Drug Administration [FDA] (2010). Guidance for industry: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. [cited on Sept 10th, 2013] http://www.fda.gov/ downloads/Drugs/.../Guidances/UCM204959.pdf
|
14 |
Fujieda M, Matsunaga A, Hayashi A, et al (2009). Children's toxicology from bench to bed - drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci, 34, 251-7.
|
15 |
Ghazali MV, Sastromihardjo S, Soedjarwo SR, et al (2011). A cross-sectional study. In 'Fundamentals of Clinical Research Methodology, Eds Sastroasmoro S and Ismael S. 4th ed. CV. Sagung Seto, Jakarta pp 130-45 (in Indonesian).
|
16 |
Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
17 |
Grover B, Buckley D, Buckley AR, et al (2004). Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther, 308, 949-56.
|
18 |
Hill GS (2008). Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens, 17, 266-70.
DOI
|
19 |
Hotta K, Matsuo K, Ueoka H, et al (2004). Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 22, 3852-9.
DOI
|
20 |
Khrunin A, Ivanova F, Moisseev A, et al (2012). Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics, 13, 171-8.
DOI
|
21 |
Kroning R, Lichtenstein AK, Nagami GT (2000). Sulfurcontaining amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol, 45, 43-9.
DOI
|
22 |
Lacy CF, Armstrong LL, Goldman MP, et al (2011). Cisplatin. In 'Drug Information Handbook'. 20th ed. Lexi Comp., Ohio, 348-9.
|
23 |
Lavole A, Danel S, Baudrin L, et al (2012). Routine administration of a single dose of cisplatin 75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer, 99, 43-8.
|
24 |
Leu L, Baribeault D (2010). A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract, 16, 167-71.
DOI
|
25 |
Morgan KP, Buie LW, Savage SW (2012). The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother, 46, 276-81.
DOI
|
26 |
Mathe C, Bohacs A, Duffek L, et al (2011). Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J, 37, 888-94.
DOI
|
27 |
Miller RP, Tadagavadi RK, Ramesh G, et al (2010). Mechanisms of cisplatin nephrotoxicity. Toxins, 2, 2490-518.
DOI
|
28 |
Moon HH, Seo KW, Yoon KY, et al (2011). Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol, 17, 3510-7.
DOI
|
29 |
Muraki K, Koyama R, Honma Y, et al (2012). Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advenced non-small cell lung cancer. J Thorac Dis, 4, 562-8.
|
30 |
Naughton CA (2008). Drug-induced nephrotoxicity. Am Fam Physician, 78, 743-50.
|
31 |
Pabla N, Dong Z (2008). Cisplatin nephrotoxicity: mechanism and renoprotective strategies. Kidney Int, 73, 994-1007.
DOI
|
32 |
Perazella MA (2009). Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol, 4, 1275-83.
DOI
ScienceOn
|
33 |
Reed E (2008). Pharmacology of cancer chemotherapy: cisplatin and its analogues. In 'Cancer Principles and Practice of Oncology', Eds De Vita VT Jr, Hellman S, Rosenberg SA. 8th ed. Lippincott Willians and Wilkins, Philadelphia.
|
34 |
Ries F, Klastersky J (1986). Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis, 8, 368-79.
DOI
|
35 |
Tan XL, Moyer AM, Fridley BL, et al (2011). Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res, 17, 5801-11.
DOI
|
36 |
Santoso JT, Lucci JA 3rd, Coleman RL, et al (2003). Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol, 52, 13-8.
DOI
|
37 |
Sinuraya ES (2012). The hospital based-cancer registry at Dharmais cancer hospital 2003- 2007. Jakarta: Indonesian J Cancer, 11-67 (in Indonesian).
|
38 |
Stevens LA, Li S, Wang C, et al (2010). Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis, 55, 23-33.
DOI
|
39 |
Tezcan S, Izzettin FV, Sancar M, et al (2013). Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol Pharmacy, 4, 296-302.
DOI
|
40 |
Thomas C, Thomas L (2009). Renal failure - measuring the glomerular filtration rate. Dtsch Arztebl Int, 106, 849-54.
|
41 |
Tiseo M, Martelli O, Mancuso A, et al (2007). Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori, 93, 138-44.
|
42 |
Wang J, Liu F, Huang DX, et al (2012). Post-operative treatment with cisplatin and vinorelbine in Chinese patients with nonsmall cell lung cancer: a clinical prospective analysis of 451 patients. Asian Pac J Cancer Prev, 13, 4505-10.
DOI
|
43 |
Yao X, Panichpisal K, Kurtzman N, et al (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334, 115-24.
DOI
|
44 |
Yamada K, Yoshida T, Zaizen Y, et al (2011). Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol, 41, 1308-11.
DOI
|